Prognostic Value of Systemic Immune-Inflammation Index in Patients with Testicular Cancer: A Retrospective Case-Control Study

Basit Öğe Kaydı
dc.contributor.authorGoger, Yunus Emre
dc.contributor.authorOzkent, Mehmet Serkan
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorUcmak, Harun
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:38:22Z
dc.date.available2024-02-23T14:38:22Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractObjective: The primary aim of this study was to evaluate the correlation between the systemic immune-inflammation index (SII) and clinicopathological outcomes of patients with testicular cancer (TCa). The secondary aim was to evaluate the relation of SII with overall survival (OS). Materials and Methods: A total of 244 patients were included in the study. Patients were divided into the testicular tumor (group 1, n=184) and control group (group 2, n=60). Preoperative complete blood count, tumor markers, and imaging tests of the patients in group 1 were recorded. A subgroup analysis was performed according to the clinical stage, pathological stage, tumor type, and tumor size. Then, the effectiveness of TCa on SII was evaluated among the groups. Results: A significant difference was observed between the SII, neutrophil, and neutrophil-to-lymphocyte ratios between groups 1 and 2. The median SII was 719.92 in group 1 and 510.93 in group 2 (p<0.001). In the subgroup analysis, the median SII value was higher in patients with advanced disease stage and metastasis (p<0.001). In the receiver operating characteristics curve analysis, the area under the curve was 0.784, and the SII cut-off point was 719, with a sensitivity of 81% and specificity of 65.4%. The median follow-up time was 55 (interquartile range, 8-132) months. Ten patients died of TCa. In the multivariable analysis, SII (7.6-fold increase; p=0.005) and presence of metastasis (4.3-fold increase; p=0.001) were independent predictors of OS. Conclusion: SII can be an important marker in the diagnosis and follow-up of TCa. However, SII needs to be evaluated using larger data, especially in the risk assessment in TCa.en_US
dc.identifier.doi10.4274/uob.galenos.2021.2021.3.2
dc.identifier.endpage257en_US
dc.identifier.issn2147-2270
dc.identifier.issue4en_US
dc.identifier.startpage252en_US
dc.identifier.urihttps://doi.org/10.4274/uob.galenos.2021.2021.3.2
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16497
dc.identifier.volume20en_US
dc.identifier.wosWOS:000731882300011en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin Of Urooncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSystemic Immune-Inflammation Indexen_US
dc.subjectTesticular Canceren_US
dc.subjectCancer Prognosisen_US
dc.subjectOverall Survivalen_US
dc.titlePrognostic Value of Systemic Immune-Inflammation Index in Patients with Testicular Cancer: A Retrospective Case-Control Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu